NCT00525720Active, not recruitingPhase 2
Brachytherapy for Prostatic Carcinoma Patients
Transperineal Interstitial Permanent Brachytherapy Alone for Selected Patients With Intermediate Risk Prostatic Carcinoma
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The goal of this clinical research study is to learn if a prostate implant (brachytherapy) can help to control intermediate risk prostate cancer. The safety of this procedure will also be studied. Prostate brachytherapy is performed by inserting permanent seeds (which are radioactive pellets) into your prostate in order to treat the prostate cancer with radiation therapy.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 300 (actual)
- First submitted
- 4 Sept 2007
- Start date
- 1 Aug 2006
- Primary completion date
- 30 Sept 2030
- Lead sponsor
- M.D. Anderson Cancer Center
- Diseases
- Prostate cancer
- NCT number
- NCT00525720
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 300
- From 1 Aug 2006 to the primary completion date, 30 Sept 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Radical surgery for carcinoma of the prostate, prior pelvic radiation, prior chemotherapy for prostate cancer, prior TURP, prior cryosurgery, TUNA, TUMT of the prostate.
Other illness
- Stage \< T1c, T2c, T3 or T4 disease (AJCC 6th Edition).
Other
- Lymph node involvement (N1).
- Evidence of distant metastases (M1).
- Active prostatitis.
Who the study is looking for
- Histologically confirmed adenocarcinoma of the prostate, clinical stage T1c - T2b (AJCC 6th Edition), N0, M0. Lymph node evaluation by either CT or MRI.
- Zubrod performance status 0-1.
- Patient must be greater than or equal to 18 years of age.
- Patients with intermediate risk prostate cancer as determined by one of the following combinations: Gleason \< 7, PSA 10-15; Gleason 7, PSA must be \< 10.
- Prostate specific antigen (PSA) prior to study entry must be less than or equal to 15 ng/ml.
- Hormone naive.
- Prostate volumes by TRUS less than or equal to 60 cc.
- AUA voiding symptom scores \</= 15 (alpha blockers allowed); this is completed by the patient.
- Patients must sign a study-specific informed consent form prior to study entry.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas - MD Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.